Shares of Gilead Sciences GILD rose 2% Thursday after the FDA approved its Yescarta lymphoma cancer therapy drug.
The greenlight comes after a six month trial.
Yescarta was developed by Kite Pharma, which Gilead acquired in August for $11.9 billion. The new drug is among the most highly anticipated on Wall Street and is expected to tally $1.7 billion in sales throughout the world over the next five years. Yescarta will cost $373,000 in the U.S.
More of What's Trending on TheStreet: